Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 7707 results

  1. FebriDx for C-reactive protein and myxovirus resistance protein A testing

      Status ...

    Diagnostics guidance
    Topic selection

  2. Helge for detecting haemolysis

      Status ...

    Diagnostics guidance
    Topic selection

  3. MolecuLight i:X for wound imaging

    The panel agreed the technology is not appropriate to be selected for guidance development as there is insufficient evidence.   ...

    Medical technologies guidance
    Topic selection

  4. NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds

      Status ...

    Medical technologies guidance
    Topic selection

  5. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]

    Awaiting development [GID-TA11565] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Botulinum toxin type A for preventing episodic migraine ID 6450

    Awaiting development [GID-TA11505] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008

      Status ...

    Technology appraisal guidance
    Topic selection

  14. IgPro20 for treating dermatomyositis TS ID 12014

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development